Boundless Bio (BOLD) Cash & Equivalents (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Cash & Equivalents of $17.5 million for Q1 2026, up 15.65% year-over-year from $15.1 million in Q1 2025, and down 2.15% quarter-over-quarter from $17.9 million in Q4 2025.
Boundless Bio (BOLD) Cash & Equivalents (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Cash & Equivalents for 4 consecutive years, with $17.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 15.65% year-over-year to $17.5 million; the TTM figure through Mar 2026 stood at $17.5 million (up 15.65% YoY), while the FY2025 annual figure was $17.9 million, down 32.79% from the prior year.
- Cash & Equivalents retreated to $17.5 million in Q1 2026 per BOLD's latest filing, from $17.9 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $117.6 million in Q3 2025 and bottomed at $14.7 million in Q2 2025.
- Historically, Cash & Equivalents has averaged $31.8 million across 4 years, with a median of $23.7 million in 2023.
- On a YoY basis, Cash & Equivalents climbed as much as 192.44% in 2025 and fell as far as 53.14% in 2025.
- Boundless Bio's Cash & Equivalents stood at $23.7 million in 2023, then advanced by 12.15% to $26.6 million in 2024, then plunged by 32.79% to $17.9 million in 2025, then retreated by 2.15% to $17.5 million in 2026.
- Business Quant data shows BOLD's Cash & Equivalents at $17.5 million in Q1 2026, $17.9 million in Q4 2025, and $117.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Boundless Bio | 67.35 Mn | 67.35 Mn | - | 72.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.60 Mn |
| Mar 31, 2026 | 17.48 Mn |
| Dec 31, 2025 | 17.87 Mn |
| Sep 30, 2025 | 117.60 Mn |
| Jun 30, 2025 | 14.70 Mn |
| Mar 31, 2025 | 15.12 Mn |
| Dec 31, 2024 | 26.59 Mn |
| Sep 30, 2024 | 40.21 Mn |
| Jun 30, 2024 | 31.36 Mn |
| Mar 31, 2024 | 25.14 Mn |
| Dec 31, 2023 | 23.71 Mn |
| Sep 30, 2023 | 20.96 Mn |
| Jun 30, 2023 | 41.32 Mn |
| Mar 31, 2023 | 21.06 Mn |